Postoperative Pain
Conditions
Brief summary
This study will compare continuous intravenous lidocaine against single-injection transversus abdominis plane (TAP) block as a modality for postoperative analgesia in kidney transplant surgery.
Detailed description
This study is a non-inferiority trial designed to assess the analgesic efficacy of an intravenous (IV) lidocaine infusion against single-injection transversus abdominis plane (TAP) block in patients undergoing kidney transplant surgery. The investigators propose a study of 124 subjects randomized into two groups. The control group will receive a TAP block. The study group will receive a continuous IV lidocaine infusion. The investigators hypothesize that there will be no statistically significant difference in postoperative opioid consumption between the two groups in the first 24 hours.
Interventions
PROCEDURETransversus Abdominis Plane Block
Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
Continuous intravenous lidocaine infusion
Sponsors
Benaroya Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Kidney transplant recipient * \>18 years old * Consent to participate
Exclusion criteria
* \<18 years old * Refusal to participate * Chronic opioid use * Seizure disorder * Allergy to local anesthestics * Severe hepatic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Opioid Consumption | 0-24 Hours | Total opioid utilization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Scores | 0-48 Hours | Numerical Rating Scale Pain Scores (Range: 0-10, where 0 is no pain and 10 is the worst pain) |
| Opioid Consumption | 24-48 Hours | Total opioid utilization |
| Opioid-Related Adverse Events | 0-48 Hours | Nausea, Vomiting, Pruritis, Respiratory Depression, Constipation |
| Block/Infusion-Related Adverse Events | 0-48 Hours | Local Anesthetic Systemic Toxicity |
| Opioid Usage | 30 days from discharge | Use of prescribed opioids |
Countries
United States
Contacts
Primary ContactNeil A Hanson, MD
Backup ContactWyndam M Strodtbeck, MD
Outcome results
None listed